ReviewProceedings (Baylor University. Medical Center)2018

Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.

Jun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.